STAA

STAAR Surgical Company

Staar Surgical along with its subsidiaries designs, develops, manufactures and sells implantable lenses and delivery systems for the eye. The Company develops, produces, and markets intraocular lenses.

STAAR Surgical Company (STAA) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (A+); its weakest is Value (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
D
Factor Score 1.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
B
Factor Score 3.3 / 5.0
Momentum
C+
Factor Score 2.6 / 5.0
Revisions
A+
Factor Score 5.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 2.6K
EV / EBITDA 36.9
Rev Growth YoY -12.0%
Gross Margin 73.6%
Price Return 3M 9.6%
Price Return 12M 2.1%
Catalyst Signal 0.00
Market Cap $1.3B
TTM Revenue $328.3M
Price / Sales 4.0
ROE 0.1%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 D (1.5) D+ (1.8) B (3.3) C+ (2.6) A+ (5.0) C+ (2.8)
2026-11-08 D (1.4) C- (2.0) B (3.3) C+ (2.7) A+ (5.0) B- (2.9)
2026-11-01 D+ (1.8) B (3.2) B (3.4) C+ (2.6) A+ (5.0) B (3.2)
2026-10-25 D+ (1.8) B (3.2) B (3.3) C (2.2) A+ (5.0) B- (3.1)
2026-10-18 C- (1.9) B (3.2) B (3.3) C (2.2) A+ (5.0) B- (3.1)
Page 1 of 8
…